Outlook for pharmaceuticals to 2012 in E7 economies, viewed by Espicom

A new collection of management reports from Espicom Business Intelligence looks at the 'E7' (Brazil, China, India, Indonesia, Mexico, Russia and Turkey) outlook for their pharmaceutical industries to 2012, finding that these countries' economies represent increasing opportunities for drugmakers constrained by maturing markets in the west.

It refers to a report from PricewaterhouseCoopers (Pharma 2020: The vision: Which path will you take?), which highlighted the dangers for the pharmaceutical industry of relying on existing mature markets such as the USA in the period to 2020. Pressures on pricing and greater payer influence will reduce the relative profitability of the USA, meaning that the industry will do well to look elsewhere for growth.

Huge potential in E7 markets

The emerging'E7 countries represent the best prospect for growth, says Espicom. The potential of these countries is huge: they have a combined population of over three billion people, and their economies are recovering from the economic downturn. One consequence of this increasing wealth is a growing financial capacity to treat previously unmet health needs. Another is increasing incidence of 'affluence' diseases such as diabetes, as people live longer and have more sedentary lifestyles.
Highlights from the report are as follows: